Latest & greatest articles for Diphtheria

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Diphtheria or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Diphtheria and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Diphtheria

1. Diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) for pregnant women: patient group direction (PGD) template

Diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) for pregnant women: patient group direction (PGD) template application/vnd.openxmlformats-officedocument.wordprocessingml.document

2019 Public Health England

2. Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study. (PubMed)

Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study. Routine childhood vaccination is among the most cost-effective, successful public health interventions available. Amid substantial investments to expand vaccine delivery throughout Africa and strengthen administrative reporting systems, most countries still require robust measures of local routine vaccine coverage and changes in geographical inequalities over time.This analysis (...) drew from 183 surveys done between 2000 and 2016, including data from 881 268 children in 49 African countries. We used a Bayesian geostatistical model calibrated to results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, to produce annual estimates with high-spatial resolution (5 ×    5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children aged 12-23 months in 52 African countries from 2000 to 2016.Estimated third-dose (DPT3) coverage

Full Text available with Trip Pro

2019 Lancet

3. Diphtheria

Diphtheria Diphtheria - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Diphtheria Last reviewed: February 2019 Last updated: March 2019 Summary Diphtheria is endemic in many areas of the world and still occurs sporadically in the US. Early intervention by administering antitoxin is key to preventing systemic manifestations of the disease, which can include respiratory and neurological symptoms, cardiovascular collapse (...) , and death. Prompt administration of antitoxin is necessary to enable it to bind to and de-activate the free toxin in serum. Antitoxin cannot de-activate toxin once it has entered cells, which is signalled by the presence of mucocutaneous symptoms. Patients with respiratory diphtheria are placed in respiratory isolation (masks and standard measures such as hand-washing), and those with cutaneous diphtheria are placed in contact isolation (gloves and gowns), until cultures taken after cessation of therapy

2019 BMJ Best Practice

4. Risk factors for diphtheria infection and persistent transmission: a systematic review

Risk factors for diphtheria infection and persistent transmission: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

5. Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder

Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder : media-1vid110.1542/5803567555001PEDS-VA_2018-0120Video Abstract BACKGROUND: Increasing vaccination of pregnant women makes it important to assess safety events potentially linked to prenatal vaccination. This study investigates the association between prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination and autism spectrum disorder (ASD) risk in offspring.This is a retrospective cohort

Full Text available with Trip Pro

2018 EvidenceUpdates

6. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les

2018 Haute Autorite de sante

7. Diphtheria

Diphtheria Diphtheria - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Diphtheria Last reviewed: February 2019 Last updated: March 2019 Summary Diphtheria is endemic in many areas of the world and still occurs sporadically in the US. Early intervention by administering antitoxin is key to preventing systemic manifestations of the disease, which can include respiratory and neurological symptoms, cardiovascular collapse (...) , and death. Prompt administration of antitoxin is necessary to enable it to bind to and de-activate the free toxin in serum. Antitoxin cannot de-activate toxin once it has entered cells, which is signalled by the presence of mucocutaneous symptoms. Patients with respiratory diphtheria are placed in respiratory isolation (masks and standard measures such as hand-washing), and those with cutaneous diphtheria are placed in contact isolation (gloves and gowns), until cultures taken after cessation of therapy

2018 BMJ Best Practice

8. Diphtheria vaccine: WHO position paper – August 2017– Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017

Diphtheria vaccine: WHO position paper – August 2017– Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017 Diphtheria vaccine: WHO position paper – August 2017– Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Diphtheria vaccine: WHO position paper – August 2017– Vaccin antidiphtérique: Note de synthèse de (...) l’OMS – août 2017 View/ Open View Statistics Altmetrics Share Citation World Health Organization = Organisation mondiale de la Santé . (‎2017)‎. Diphtheria vaccine: WHO position paper – August 2017– Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire, 92 (‎31)‎, 417 - 435. World Health Organization = Organisation mondiale de la Santé. Journal Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire, 92 (‎31

2017 WHO

10. Update on Immunization and Pregnancy Tetanus Diphtheria and Pertussis Vaccination

Update on Immunization and Pregnancy Tetanus Diphtheria and Pertussis Vaccination Update on Immunization and Pregnancy Tetanus Diphtheria and Pertussis Vaccination - ACOG Menu ▼ Update on Immunization and Pregnancy Tetanus Diphtheria and Pertussis Vaccination Page Navigation ▼ Number 718, September 2017 (Replaces Committee Opinion 566, June 2013) Committee on Obstetric Practice Immunization and Emerging Infections Expert Work Group This Committee Opinion was developed by the Immunization (...) , or consequential damages, incurred in connection with this publication or reliance on the information presented. Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination ABSTRACT: The overwhelming majority of morbidity and mortality attributable to pertussis infection occurs in infants who are 3 months and younger. Infants do not begin their own vaccine series against pertussis until approximately 2 months of age. This leaves a window of significant vulnerability for newborns, many

2017 American College of Obstetricians and Gynecologists

11. Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) 17 December 2015 EMA/CHMP/72003/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Vaxelis Common name: diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) Procedure No. EMEA/H/C/003982/0000 Note (...) 132 4. Recommendations 139 Assessment report EMA/CHMP/72003/2016 Page 4/140 List of abbreviations AAHS Aluminium Hydroxyphosphate Sulfate AlPO4 aluminium phosphate aP acellular pertussis BAP Bulk alum Product BSA Bovine Serum Albumin CHO Chinese Hamster Ovary CPP Critical Process Parameters CPVS Concentrated Purified Viral Suspension CQAs Critical Quality Attributes D Diphtheria DNA Deoxyribonucleic Acid DP Drug Product dPRP derivatised Polyribosyl Ribitol Phosphate DS Drug substance ELISA Enzyme

2016 European Medicines Agency - EPARs

12. Pertussis-tetanus-diphtheria-polio vaccines

Pertussis-tetanus-diphtheria-polio vaccines USE OF PERTUSSIS/TETANUS/DIPHTHERIA/POLIO VACCINES IN PREGNANCY 0344 892 0909 USE OF PERTUSSIS/TETANUS/DIPHTHERIA/POLIO VACCINES IN PREGNANCY (Date of issue: November 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information (...) leaflet on is available at . Summary The Joint Committee on Vaccination and Immunisation recommends that all pregnant women in the UK are vaccinated with Boostrix IPV ® (a combined, inactivated tetanus/diphtheria/acellular pertussis/polio (Tdap-IPV) vaccine) between 16 and 32 weeks of gestation. Infants under the age of three months are at increased risk of severe complications of pertussis infection, including death. Maternal vaccination between 16 and 32 weeks of pregnancy is thought to optimise

2014 UK Teratology Information Service

13. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. (PubMed)

Safety and immunogenicity of tetanus diphtheria and acellular pertussis (tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine could prevent infant pertussis.To evaluate the safety and immunogenicity of Tdap immunization during pregnancy and its effect on infant responses to diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine.Phase 1-2

Full Text available with Trip Pro

2014 JAMA

14. Hexyon - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed)

Hexyon - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed) 5 March 2013 EMA/373968/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Hexyon Common name: Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) Procedure No.: EMEA/H/C/002796 Note (...) of the dossier 6 1.2. Steps taken for the assessment of the product 7 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 11 2.2.1. Introduction 11 2.2.2. Purified Diphtheria Toxoid (PDT) 11 2.2.3. Purified Tetanus Toxoid (PTT) 12 2.2.4. Acellular Pertussis (adsorbed PTxd and adsorbed FHA) 13 2.2.5. PRP-T Drug Substance 14 2.2.6. IPV Drug Substance 16 2.2.7. HBsAg Drug Substance 16 2.2.8. Finished Medicinal Product 18 2.2.9. Discussion on chemical, pharmaceutical and biological aspects 23

2013 European Medicines Agency - EPARs

15. Hexacima - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed)

Hexacima - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type-b conjugate vaccine (adsorbed) 5 March 2013 EMA/373868/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Hexacima Common name: Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type B conjugate vaccine (adsorbed) Procedure No.: EMEA/H/C/002702 (...) of the dossier 6 1.2. Steps taken for the assessment of the product 7 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 11 2.2.1. Introduction 11 2.2.2. Purified Diphtheria Toxoid (PDT) 11 2.2.3. Purified Tetanus Toxoid (PTT) 12 2.2.4. Acellular Pertussis (adsorbed PTxd and adsorbed FHA) 13 2.2.5. PRP-T Drug Substance 14 2.2.6. IPV Drug Substance 16 2.2.7. HBsAg Drug Substance 16 2.2.8. Finished Medicinal Product 17 2.2.9. Discussion on chemical, pharmaceutical and biological aspects 23

2013 European Medicines Agency - EPARs

16. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). (PubMed)

Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Advantages to combining childhood vaccines include reducing the number of visits, injections and patient discomfort, increasing compliance and optimising prevention. The World Health Organization (WHO) recommends that routine infant immunisation programmes include a vaccination against Haemophilus (...) influenzae (H. influenzae) type B (HIB) in the combined diphtheria-tetanus-pertussis (DTP)-hepatitis B virus (HBV) vaccination. The effectiveness and safety of the combined vaccine should be carefully and systematically assessed to ensure its acceptability by the community.To compare the effectiveness of combined DTP-HBV-HIB vaccines versus combined DTP-HBV and separate HIB vaccinations.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 4), which

2012 Cochrane

17. Tetrabik (adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) combined vaccine)

Tetrabik (adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) combined vaccine) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Report on the Deliberation Results July 23, 2012 (...) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Tetrabik Subcutaneous Injection Syringe [Non-proprietary name] Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio (Sabin strain) Combined Vaccine [Applicant] The Research Foundation for Microbial Diseases of Osaka University [Date of application] December 27, 2011 [Results of deliberation] In the meeting held on July 20, 2012, the Second Committee on New Drugs

2012 Pharmaceuticals and Medical Devices Agency, Japan

18. Quattrovac (adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) combined vaccine)

Quattrovac (adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain) combined vaccine) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Report on the Deliberation Results July 23, 2012 (...) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Quattrovac Subcutaneous Injection Syringe [Non-proprietary name] Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio (Sabin strain) Combined Vaccine [Applicant] The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN) [Date of application] January 27, 2012 [Results of deliberation] In the meeting held on July 20, 2012, the Second Committee on New Drugs concluded

2012 Pharmaceuticals and Medical Devices Agency, Japan

19. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. (PubMed)

Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage. Substantial resources have been invested in increasing childhood immunisation coverage through global initiatives such as the Universal Childhood Immunisation (UCI) campaign and the Global Alliance on Vaccines and Immunisations (GAVI). There are longstanding concerns that target-oriented and performance (...) -oriented initiatives such as UCI and GAVI's immunisation services support (ISS) might encourage over-reporting. We estimated the coverage of three doses of diphtheria, tetanus, and pertussis vaccine (DTP3) based on surveys using all available data.We estimated DTP3 coverage by analysing unit record data from surveys and supplemented this with reported coverage from other surveys and administrative data. We used bidirectional distance-dependent regression to estimate trends in survey-based coverage

2008 Lancet

20. Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma (PubMed)

Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma Early childhood immunizations have been viewed as promoters of asthma development by stimulating a T(H)2-type immune response or decreasing microbial pressure, which shifts the balance between T(H)1 and T(H)2 immunity.Differing time schedules for childhood immunizations may explain the discrepant findings of an association with asthma reported in observational studies. This research (...) was undertaken to determine whether timing of diphtheria, pertussis, tetanus (DPT) immunization has an effect on the development of childhood asthma by age 7 years.This was a retrospective longitudinal study of a cohort of children born in Manitoba in 1995. The complete immunization and health care records of cohort children from birth until age 7 years were available for analysis. The adjusted odds ratio for asthma at age 7 years according to timing of DPT immunization was computed from multivariable

2008 EvidenceUpdates